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LETTER TO THE EDITOR
Breast cancer and combined oral contraceptives
Sir - The article on the WHO-supported study (WHO, 1989)
on breast cancer and combined oral contraceptives (OCs) is
an excellent illustration of the limits of epidemiology when
relative risks are close to 1.0 and numerous small biases
become potentially important. It discusses a number of biases
which might explain the slightly elevated relative risks of 1.07
and 1.24, for developed and developing countries respec-
tively. Another source of bias, however, could possibly ex-
plain the higher relative risk in developing countries and the
higher relative risk with recent OC use. This potential bias
relates to the characteristics of controls in this kind of
hospital-based, case-control study.
Especially in developing countries, it seems likely that
hospitalised controls may often have chronic underlying con-
ditions (such as tuberculosis, fungal infections, malaria, prior
severe trauma, parasitic diseases, nutritional disorders, such
as rickets, etc.) other than those conditions excluded from the
study because they are related to OC use. Also, irrespective
of diagnosis, admission to a hospital is often not an isolated
event, but rather only the latest in a series of admissions.
This phenomenon may be especially common in referral
hospitals such as may have been used in the WHO study.
Such hospital controls might use less OCs for 2 reasons.
First, such women may be less sexually active and, in
general, use contraception less. Second, there may be a
general reluctance among health providers, and women
themselves, to use oral contraceptives in the context of any
existing medical condition because of a generalised anxiety
about OCs. If control subjects have artifically low OC use,
observed relative risks for breast cancer among OC users
may be inflated. The phenomenon would be operative across
diagnostic categories and therefore the observation that
use of oral contraceptives did not vary greatly among women
in the various diagnostic categories' does not rule out the
phenomenon. Further, the bias could also occur in seemingly
unrelated acute admission conditions. For example, women
with fractures or other trauma might be more likely to be
admitted to hospitals if they also had chronic tuberculosis.
Regarding recency, the bias might be expected to be more
operative in recent times since it reflects a current disease
status which may have been less severe or less of an issue in
previous years. Also, generalised medical concern among
health pracitioners about oral contraceptives seems to have
increased in more recent years. Recency of course also raises
the suspicion of detection bias.
The investigators selected the use of hospital controls, in
part, to minimise a potential medical attention bias. That
very choice, however, may have introduced a different con-
trol selection bias. The bias may be subtle, but in dealing
with relative risks of about 1.1 or 1.2, subtle effects must be
considered. In instances such as this, authors should provide,
as a minimum, a complete description of both admission and
underlying diagnosis of controls and, if possible, information
on previous hospital admissions. One would be particularly
interested in the centre in Chiang Mai, Thailand, since it
seems to account for much of the observed higher relative
risk.
Yours etc.
J.D. Shelton,
Office of Population,
Agency for International Development,
Washington, DC 20523, USA.
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